Vertex Pharmaceuticals (VRTX)
VRTX (NASDAQ:Drugs)
$79.49
+1.60
+2.05%
Today's Range: 77.69 - 79.54 |
VRTX Avg Daily Volume: 2,520,000
| Last Update: 05/17/13 - 4:00 PM EDT |
| Volume: 2,622,604 |
| YTD Performance: 85.90%
|
| Open: $78.72 |
| Previous Close: $77.89 |
| 52 Week Range: $38.44 -
$87.47 |
| Oustanding Shares: 221,400,864 |
| Market Cap: 17,244,913,297 |
6-Month Chart
TheStreet Ratings Grade for VRTX
| Buy |
Hold
|
Sell
|
| A+ |
A |
A- |
B+ |
B |
B- |
C+ |
C |
C- |
D+ |
D |
D- |
E+ |
E |
E- |
F |
Analysts Ratings
| Historical Rec |
Current |
1 Mo. Ago |
2 Mo. Ago |
3 Mo. Ago |
| Strong Buy |
12 |
12 |
12 |
12 |
| Moderate Buy |
2 |
2 |
2 |
2 |
| Hold |
5 |
6 |
5 |
5 |
| Moderate Sell |
0 |
0 |
0 |
0 |
| Strong Sell |
0 |
0 |
0 |
0 |
| Mean Rec. |
1.63 |
1.70 |
1.63 |
1.63 |
| Latest Dividend: |
0.00 |
| Latest Dividend Yield: |
0.00% |
| Dividend Ex-Date: |
08/24/00 |
| Price Earnings Ratio: |
-33.00 |
|
| Price Earnings Comparisons: |
| VRTX |
Sector Avg. |
S&P 500 |
| -33.00 |
0.00 |
17.70 |
| Price Performance History (%Change): |
| 3 Mo |
1 Yr |
3 Y |
|
70.77%
|
26.96%
|
107.93%
|
|
| GROWTH |
12 Mo |
3 Yr |
CAGR |
| Revenue |
8.30 |
13.99 |
1.44 |
| Net Income |
-100.00 |
-0.92 |
0.00 |
| EPS |
-100.00 |
-0.87 |
0.00 |
| Earnings for VRTX: |
| EBITDA |
0.04B |
| Revenue |
1.53B |
|
Average Earnings Estimates
;Qtr (09/13);FY (12/13);FY (12/14)&HEADING_LIST1=Qtr (06/12);Qtr (09/12);FY (12/12);FY (12/13)) |
|
| Average Estimate |
$-0.21 |
$-0.26 |
$-2.13 |
$-1.42 |
| Number of Analysts |
7 |
7 |
10 |
10 |
| High Estimate |
$-0.12 |
$-0.19 |
$-1.00 |
$0.15 |
| Low Estimate |
$-0.32 |
$-0.38 |
$-2.56 |
$-2.69 |
| Prior Year |
$0.33 |
$0.00 |
$0.68 |
$-2.13 |
| Growth Rate (Year over Year) |
-162.77% |
n.a.% |
-412.79% |
33.29% |
May 13, 2013 | 4:08 PM EDT
| May 10, 2013 | 4:15 PM EDT
The action just keeps chugging higher.
May 01, 2013 | 7:40 AM EDT
VRTX earnings estimates were increased to reflect faster penetration of CF, said UBS. Price target goes to $86.
| Apr 19, 2013 | 4:32 PM EDT
I'm going to spend some time developing my watch list for next week.
Apr 19, 2013 | 8:07 AM EDT
VRTX's price target was increased to $100, said Deutsche Bank. F508del homozygous and other Kalydeco mutations are now expected to have...
Apr 08, 2013 | 7:23 AM EDT
VRTX was initiated with a Hold rating, Canaccord Genuity said. Valuation call, based on a $55 price target.
Mar 19, 2013 | 8:22 AM EDT
VRTX earnings estimates were increased after speaking with physicians about the cystic fibrosis trial that is set to launch, said JPMor...
Feb 07, 2013 | 6:51 AM EST
VRTX was initiated with an Outperform rating, Robert Baird said. $53 price target. Cystic Fibrosis franchise can drive growth.
&n...
Jan 15, 2013 | 8:27 AM EST
VRTX was downgraded to Neutral, Lazard Capital Markets said. Company is likely facing a transition year.
Nov 12, 2012 | 6:49 AM EST
VRTX was downgraded from Outperform to Neutral, Credit Suisse said. $48 price target. Company will likely see lower Incivek sales. ...
